{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:00:30Z","timestamp":1790298030328,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.pupt.2026.102451","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:42:07Z","timestamp":1790178127000},"page":"102451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Steroid-sparing strategies in respiratory diseases: efficacy and safety of current therapeutic options"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5504-6940","authenticated-orcid":false,"given":"Mateusz","family":"Gadza\u0142a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2511-6811","authenticated-orcid":false,"given":"Aleksandra","family":"Pa\u017a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6294-3256","authenticated-orcid":false,"given":"Dagmara","family":"Mirowska-Guzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pupt.2026.102451_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00703-2018","article-title":"Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature","volume":"52","author":"Volmer","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2026.102451_bib2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.pupt.2026.102451_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1310211","article-title":"Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases","volume":"14","author":"del Pozo","year":"2024","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.pupt.2026.102451_bib4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/0145561320967727","article-title":"A scholarly review of the safety and efficacy of intranasal corticosteroids preparations in the treatment of chronic rhinosinusitis","volume":"100","author":"Psaltis","year":"2021","journal-title":"Ear Nose Throat J."},{"key":"10.1016\/j.pupt.2026.102451_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000336185","article-title":"Corticosteroid-sparing agents: conventional systemic immunosuppressants","volume":"51","author":"Kruh","year":"2012","journal-title":"Dev. Ophthalmol."},{"key":"10.1016\/j.pupt.2026.102451_bib6","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s12026-024-09463-y","article-title":"Assessing the steroid-sparing effect of biological agents in randomized controlled trials for lupus: a scoping review","volume":"72","author":"Sciascia","year":"2024","journal-title":"Immunol. Res."},{"issue":"20","key":"10.1016\/j.pupt.2026.102451_bib7","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.pupt.2026.102451_bib8","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaip.2022.12.012","article-title":"Omalizumab in allergic bronchopulmonary aspergillosis: a systematic review and meta-analysis","volume":"11","author":"Jin","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"2","key":"10.1016\/j.pupt.2026.102451_bib9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00408-021-00436-8","article-title":"Tofacitinib as a steroid-sparing therapy in pulmonary sarcoidosis, an open-label prospective proof-of-concept study","volume":"199","author":"Friedman","year":"2021","journal-title":"Lung"},{"issue":"8","key":"10.1016\/j.pupt.2026.102451_bib10","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.jaip.2025.04.032","article-title":"Impact of biologics initiation on oral corticosteroid use in the International Severe Asthma Registry and the Optimum Patient Care Research Database: a pooled analysis of real-world data","volume":"13","author":"Chen","year":"2025","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"8","key":"10.1016\/j.pupt.2026.102451_bib11","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1093\/rheumatology\/keaf240","article-title":"The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitis","volume":"64","author":"Biddle","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.pupt.2026.102451_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103219","article-title":"Eosinophilic granulomatosis with polyangiitis: a review","volume":"22","author":"White","year":"2023","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.pupt.2026.102451_bib13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.pupt.2026.102451_bib14","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.pupt.2026.102451_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejim.2021.08.021","article-title":"Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis","volume":"95","author":"R\u00edos-Garc\u00e9s","year":"2022","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.pupt.2026.102451_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1341310","article-title":"Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis","volume":"11","author":"Desaintjean","year":"2024","journal-title":"Front. Med."},{"issue":"11","key":"10.1016\/j.pupt.2026.102451_bib17","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.ard.2025.06.2131","article-title":"Two-year efficacy and safety of anti-interleukin-5\/receptor therapy for eosinophilic granulomatosis with polyangiitis","volume":"84","author":"Merkel","year":"2025","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.pupt.2026.102451_bib18","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/mr\/road104","article-title":"Trends in prevalence, treatment use, and disease burden in patients with eosinophilic granulomatosis with polyangiitis in Japan: real-world database analysis","volume":"34","author":"Sada","year":"2024","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.pupt.2026.102451_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152609","article-title":"Defining cause of death in a contemporary cohort with ANCA-associated vasculitis (AAV): a comparison of electronic health record and death certificate data","volume":"70","author":"Katz","year":"2025","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.pupt.2026.102451_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.918356","article-title":"High mortality rate in oral glucocorticoid users: a population-based matched cohort study","volume":"13","author":"Einarsdottir","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"10.1016\/j.pupt.2026.102451_bib23","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00803-2024","article-title":"Fungal lung disease","volume":"64","author":"Jaggi","year":"2024","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.pupt.2026.102451_bib24","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00061-2024","article-title":"Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis\/mycoses","volume":"63","author":"Agarwal","year":"2024","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.pupt.2026.102451_bib25","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.1038\/s41598-023-32246-8","article-title":"Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosis","volume":"13","author":"Tomomatsu","year":"2023","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.pupt.2026.102451_bib26","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jaip.2020.03.023","article-title":"Mepolizumab for allergic bronchopulmonary aspergillosis: report of 20 cases from the Belgian Severe Asthma Registry and review of the literature","volume":"8","author":"Schleich","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"Suppl 1","key":"10.1016\/j.pupt.2026.102451_bib27","article-title":"Dupilumab improves lung function, asthma control and exacerbation frequency in allergic bronchopulmonary aspergillosis: results from the phase 2 LIBERTY ABPA AIRED study","volume":"211","author":"Bourdin","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.pupt.2026.102451_bib28","article-title":"Anti-IL-4R\u03b1 therapy is superior to other biologic classes in treating allergic bronchopulmonary aspergillosis","volume":"4","author":"Lamothe","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"issue":"Suppl 2","key":"10.1016\/j.pupt.2026.102451_bib29","first-page":"A114","article-title":"S163 managing ABPA with tezepelumab: a single-centre experience","volume":"80","author":"Sehajpal","year":"2025","journal-title":"Thorax"},{"issue":"19","key":"10.1016\/j.pupt.2026.102451_bib30","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.pupt.2026.102451_bib31","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJM200003163421102","article-title":"A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis","volume":"342","author":"Stevens","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.pupt.2026.102451_bib32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.15586\/aei.v54i2.1623","article-title":"Stepwise, precision-based management of allergic bronchopulmonary aspergillosis\/mycosis: a real-life multicenter study","volume":"54","author":"\u00d6zden","year":"2026","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.pupt.2026.102451_bib33","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.3390\/ijms27125335","article-title":"New therapies for sarcoidosis: molecular and pathophysiological basis","volume":"27","author":"Drakopanagiotakis","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pupt.2026.102451_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103107","article-title":"Pulmonary sarcoidosis: a comprehensive review: past to present","volume":"149","author":"Belperio","year":"2024","journal-title":"J. Autoimmun."},{"issue":"6","key":"10.1016\/j.pupt.2026.102451_bib35","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur. Respir. J."},{"issue":"155","key":"10.1016\/j.pupt.2026.102451_bib36","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0146-2019","article-title":"Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis","volume":"29","author":"Rahaghi","year":"2020","journal-title":"Eur. Respir. Rev."},{"issue":"3","key":"10.1016\/j.pupt.2026.102451_bib37","first-page":"217","article-title":"Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: a single center real-world study","volume":"36","author":"Fang","year":"2019","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"3","key":"10.1016\/j.pupt.2026.102451_bib38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa2501443","article-title":"First-line treatment of pulmonary sarcoidosis with prednisone or methotrexate","volume":"393","author":"Kahlmann","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.pupt.2026.102451_bib39","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12931-024-02758-6","article-title":"Efficacy and safety of infliximab in systemic sarcoidosis according to GenPhenReSa organ-involvement phenotype: a retrospective study of 55 patients","volume":"25","author":"Rivi\u00e8re","year":"2024","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.pupt.2026.102451_bib40","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12931-022-01971-5","article-title":"Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis","volume":"23","author":"Sakkat","year":"2022","journal-title":"Respir. Res."},{"key":"10.1016\/j.pupt.2026.102451_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.545413","article-title":"Treatment of sarcoidosis: a multidisciplinary approach","volume":"11","author":"Gerke","year":"2020","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.pupt.2026.102451_bib42","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1378\/chest.12-1728","article-title":"Methotrexate vs azathioprine in second-line therapy of sarcoidosis","volume":"144","author":"Vorselaars","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2026.102451_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1258236","article-title":"Exposure-response analyses of efzofitimod in patients with pulmonary sarcoidosis","volume":"14","author":"Walker","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.pupt.2026.102451_bib44","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1056\/NEJM200008033430504","article-title":"Low-Dose inhaled corticosteroids and the prevention of death from asthma","volume":"343","author":"Suissa","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.pupt.2026.102451_bib46","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01147-2019","article-title":"Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma","volume":"55","author":"Maijers","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.pupt.2026.102451_bib47","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1164\/rccm.202402-0368OC","article-title":"Association of dose of inhaled corticosteroids and frequency of adverse events","volume":"211","author":"Bloom","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2026.102451_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107414","article-title":"Biologics in severe asthma: a pragmatic approach for choosing the right treatment for the right patient","volume":"218","author":"Rogers","year":"2023","journal-title":"Respir. Med."},{"key":"10.1016\/j.pupt.2026.102451_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.108312","article-title":"Substantial reduction in oral corticosteroid use after biologics initiation in severe asthma: an analysis based on Swiss pharmacy data","volume":"248","author":"Bridevaux","year":"2025","journal-title":"Respir. Med."},{"issue":"2","key":"10.1016\/j.pupt.2026.102451_bib50","doi-asserted-by":"crossref","first-page":"99","DOI":"10.32383\/farmpol\/211702","article-title":"Effect of glucocorticoids on peripheral blood cell populations: a review of current evidence","volume":"81","author":"Gadza\u0142a","year":"2025","journal-title":"Farm. Pol."},{"issue":"5","key":"10.1016\/j.pupt.2026.102451_bib55","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaci.2022.05.024","article-title":"Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis","volume":"150","author":"Akenroye","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2026.102451_bib52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/JAA.S432695","article-title":"Real-world safety and effectiveness of benralizumab in Japanese patients with severe asthma: a multicenter prospective observational study","volume":"17","author":"Yamaguchi","year":"2024","journal-title":"J. Asthma Allergy"},{"issue":"1","key":"10.1016\/j.pupt.2026.102451_bib53","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","article-title":"Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial","volume":"7","author":"Busse","year":"2019","journal-title":"Lancet Respir. Med."},{"issue":"12","key":"10.1016\/j.pupt.2026.102451_bib54","article-title":"Efficacy and safety of mepolizumab in the management of severe eosinophilic asthma: a systematic review","volume":"15","author":"Dighriri","year":"2023","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.pupt.2026.102451_bib58","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.pupt.2026.102451_bib61","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaci.2024.11.005","article-title":"Omalizumab safety concerns","volume":"155","author":"Pongdee","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"issue":"10","key":"10.1016\/j.pupt.2026.102451_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100695","article-title":"Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma","volume":"15","author":"Hanania","year":"2022","journal-title":"World Allergy Organ. J."},{"key":"10.1016\/j.pupt.2026.102451_bib63","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.rmed.2017.07.013","article-title":"Long-term \u201creal-life\u201d safety of omalizumab in patients with severe uncontrolled asthma: a nine-year study","volume":"130","author":"Di Bona","year":"2017","journal-title":"Respir. Med."},{"issue":"5","key":"10.1016\/j.pupt.2026.102451_bib64","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","article-title":"Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study","volume":"11","author":"Menzies-Gow","year":"2023","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.pupt.2026.102451_bib65","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/02770903.2024.2385973","article-title":"Long-term safety of tezepelumab in patients with asthma: a systematic review and meta-analysis of randomized controlled trials","volume":"62","author":"Qin","year":"2025","journal-title":"J. Asthma"},{"issue":"3","key":"10.1016\/j.pupt.2026.102451_bib66","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jcpt.12148","article-title":"Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events","volume":"39","author":"Mendes","year":"2014","journal-title":"J. Clin. Pharm. Therapeut."},{"issue":"6","key":"10.1016\/j.pupt.2026.102451_bib73","doi-asserted-by":"crossref","first-page":"518","DOI":"10.5603\/PiAP.2014.0069","article-title":"Methotrexate as a single agent for treating pulmonary sarcoidosis: a single centre real-life prospective study","volume":"82","author":"Goljan-Geremek","year":"2014","journal-title":"Adv Respir Med."},{"key":"10.1016\/j.pupt.2026.102451_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1320458","article-title":"A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database","volume":"14","author":"Zou","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.pupt.2026.102451_bib56","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1080\/02770903.2024.2311236","article-title":"Biologics for asthma and risk of pneumonia","volume":"61","author":"Matera","year":"2024","journal-title":"J. Asthma"},{"key":"10.1016\/j.pupt.2026.102451_bib57","article-title":"Prospective REALITI-A study: 2-year real-world benefits of mepolizumab in severe asthma","volume":"2","author":"Caruso","year":"2024","journal-title":"CHEST Pulm"},{"issue":"8","key":"10.1016\/j.pupt.2026.102451_bib59","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jamadermatol.2024.1536","article-title":"Dupilumab in adults with moderate to severe atopic dermatitis: a 5-year open-label extension study","volume":"160","author":"Beck","year":"2024","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.pupt.2026.102451_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.992731","article-title":"Dupilumab efficacy and safety in patients with moderate to severe asthma: a systematic review and meta-analysis","volume":"13","author":"Zaazouee","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.pupt.2026.102451_bib67","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/ecco-jcc\/jjaa186","article-title":"TNF inhibitors and risk of malignancy in patients with inflammatory bowel diseases: a systematic review","volume":"15","author":"Muller","year":"2021","journal-title":"J. Crohns Colitis"},{"issue":"8","key":"10.1016\/j.pupt.2026.102451_bib68","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.pupt.2026.102451_bib69","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12950-025-00445-x","article-title":"Long-term risk of de novo malignancy with tumor necrosis factor alpha (TNF) inhibitor immunosuppression: a multicenter, retrospective cohort study","volume":"22","author":"Driscoll","year":"2025","journal-title":"J Inflamm (Lond)"},{"issue":"5","key":"10.1016\/j.pupt.2026.102451_bib70","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/apt.15637","article-title":"Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System","volume":"51","author":"Shah","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.pupt.2026.102451_bib71","doi-asserted-by":"crossref","DOI":"10.5070\/D330263575","article-title":"Merkel cell carcinoma associated with TNF inhibitor therapy: a systematic review of case reports","volume":"30","author":"Almashali","year":"2024","journal-title":"Dermatol. Online J."},{"issue":"7","key":"10.1016\/j.pupt.2026.102451_bib72","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1136\/annrheumdis-2015-208263","article-title":"Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden","volume":"75","author":"Wadstr\u00f6m","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.pupt.2026.102451_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153740","article-title":"Safety and efficacy of methotrexate in psoriasis: a meta-analysis of published trials","volume":"11","author":"West","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.pupt.2026.102451_bib75","article-title":"Safety profile of methotrexate therapy in patients with rheumatoid arthritis","volume":"14","author":"Mustafa","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.pupt.2026.102451_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107655","article-title":"Navigating biologic therapies in elderly asthma","volume":"227","author":"Ji","year":"2024","journal-title":"Respir. Med."},{"issue":"9","key":"10.1016\/j.pupt.2026.102451_bib77","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afac203","article-title":"Sarcoidosis in the older person: diagnostic challenges and treatment consideration","volume":"51","author":"Brennan","year":"2022","journal-title":"Age Ageing"},{"issue":"176","key":"10.1016\/j.pupt.2026.102451_bib78","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0269-2024","article-title":"Safety of biologics for the treatment of asthma in children and adolescents: a systematic review","volume":"34","author":"Wirthgen","year":"2025","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.pupt.2026.102451_bib79","doi-asserted-by":"crossref","DOI":"10.1177\/17534666251319175","article-title":"Adverse effects of biologics used to treat asthma","volume":"19","author":"Sitek","year":"2025","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"4","key":"10.1016\/j.pupt.2026.102451_bib80","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1093\/rheumatology\/keac551","article-title":"British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids","volume":"62","author":"Russell","year":"2023","journal-title":"Rheumatology (Oxford)"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553926000441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553926000441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:17:34Z","timestamp":1790295454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553926000441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":77,"alternative-id":["S1094553926000441"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2026.102451","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Steroid-sparing strategies in respiratory diseases: efficacy and safety of current therapeutic options","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2026.102451","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102451"}}